Evidence map›Paper›PMID 30709862›Full record

ArticleBMJ open2019

Metastatic breast cancer incidence, site and survival in Australia, 2001-2016: a population-based health record linkage study protocol.

Sarah J Lord, Belinda E Kiely, Sallie-Anne Pearson, Benjamin Daniels, Dianne L O'Connell, Jane Beith, Max K Bulsara, Nehmat Houssami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. EClinicalMedicine · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sarah J LordThe School of Medicine, University of Notre Dame Australia - Darlinghurst, Darlinghurst, New South Wales, Australia.ORCID 0000-0003-2763-5949
Belinda E KielyNational Health and Medical Research Council (NHMRC) Clinical Trials Centre, The University of Sydney, Camperdown, New South Wales, Australia.
Sallie-Anne PearsonThe Centre for Big Data Research in Health, The University of NSW, Kensington, NSW, Australia.
Benjamin DanielsThe Centre for Big Data Research in Health, The University of NSW, Kensington, NSW, Australia.
Dianne L O'ConnellCancer Research Division, Cancer Council NSW, Woolloomooloo, New South Wales, Australia.
Jane BeithChris O'Brien Lifehouse, Camperdown, The University of Sydney, Camperdown, New South Wales, Australia.
Max K BulsaraThe Institute of Health Research and the School of Medicine, University of Notre Dame, Fremantle, Western Australia, Australia.
Nehmat HoussamiSydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAdvances in systemic therapy for early and metastatic breast cancer (BC) over the last two decades have improved patients' survival, but their impact on metastatic disease outcomes at a population level is not well described. The aim of this study is to investigate changes in the incidence, site and survival of metastatic disease for women with a first diagnosis of BC in 2001-2002 vs 2006-2007. METHODS AND ANALYSIS: Population-based retrospective cohort study of women with first primary invasive BC registered in the New South Wales (NSW) Cancer Registry in 2001-2002 and 2006-2007. We will use linked records from NSW hospitals, dispensed medicines, outpatient services and death registrations to determine: women's demographic and tumour characteristics; treatments received; time to first distant metastasis; site of first metastasis and survival. We will use the Kaplan-Meier method to estimate cumulative incidence of distant metastasis, distant recurrence-free interval and postmetastasis survival by extent of disease at initial diagnosis, site of metastasis and treatment-defined tumour receptor type (hormone receptor-positive, human epidermal growth factor receptor-2-positive, triple negative). We will use Cox proportional hazards regression to estimate the relative effects of prognostic factors, and we will compare systemic therapy patterns by area-of-residence and area-level socioeconomic status to examine equity of access to healthcare. ETHICS AND DISSEMINATION: Research ethics committee approval was granted by the Australian Institute of Health and Welfare (#EO2017/2/255), NSW Population and Health Services (#HREC/17/CIPHS/19) and University of Notre Dame Australia (#0 17 144S). We will disseminate research findings to oncology, BC consumer and epidemiology audiences through national and international conference presentations, lay summaries to BC consumer groups and publications in international peer-reviewed oncology and cancer epidemiology journals.

Indexed as

Neoplasm MetastasisRegistriesResearch DesignBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansIncidenceNeoplasm StagingNew South WalesPrognosisRetrospective StudiesSurvival AnalysisErb-b2 Receptor Tyrosine Kinasesbreast tumoursdistant recurrence-free intervalepidemiologyhealth record linkagemetastatic breast cancerprognosis

Identifiers

PMID30709862
PMCPMC6367965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.